Danaher Co. (NYSE:DHR) Shares Bought by Mill Creek Capital Advisors LLC

Mill Creek Capital Advisors LLC raised its holdings in shares of Danaher Co. (NYSE:DHR) by 7.2% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,838 shares of the conglomerate’s stock after acquiring an additional 191 shares during the quarter. Mill Creek Capital Advisors LLC’s holdings in Danaher were worth $709,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Tsfg LLC increased its stake in Danaher by 733.3% in the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after purchasing an additional 88 shares during the last quarter. nVerses Capital LLC acquired a new stake in Danaher during the 2nd quarter worth $25,000. CarsonAllaria Wealth Management Ltd. purchased a new stake in Danaher in the second quarter valued at $25,000. Cape Investment Advisory Inc. acquired a new position in Danaher in the fourth quarter valued at $25,000. Finally, Redmont Wealth Advisors LLC purchased a new position in shares of Danaher during the first quarter worth about $30,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Stock Performance

DHR opened at $273.19 on Tuesday. Danaher Co. has a 1-year low of $182.09 and a 1-year high of $281.70. The stock has a market cap of $202.35 billion, a P/E ratio of 46.30, a P/E/G ratio of 4.48 and a beta of 0.83. The stock’s 50 day simple moving average is $268.16 and its 200 day simple moving average is $257.32. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same quarter in the previous year, the company posted $2.05 EPS. The business’s revenue was down 2.9% on a year-over-year basis. As a group, equities analysts anticipate that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.40%. The ex-dividend date of this dividend is Friday, September 27th. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Insiders Place Their Bets

In related news, SVP Georgeann Couchara sold 952 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other Danaher news, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the transaction, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Rainer Blair sold 9,007 shares of the company’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the transaction, the chief executive officer now owns 97,983 shares of the company’s stock, valued at $27,435,240. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 39,659 shares of company stock valued at $11,042,433. Corporate insiders own 11.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Evercore ISI decreased their target price on Danaher from $266.00 to $260.00 and set an “outperform” rating for the company in a research report on Tuesday, July 2nd. Leerink Partners lifted their target price on shares of Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. Bank of America increased their price target on shares of Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 24th. TD Cowen upped their target price on shares of Danaher from $290.00 to $310.00 and gave the company a “buy” rating in a report on Wednesday, July 24th. Finally, Wells Fargo & Company initiated coverage on Danaher in a report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price target on the stock. Seven equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Danaher currently has an average rating of “Moderate Buy” and an average price target of $278.94.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.